



Final Appraisal Recommendation

Advice number: 1722 – September 2022

**Lacosamide (Vimpat®) 50 mg, 100 mg, 150 mg, 200 mg
film-coated tablets, 10 mg/ml syrup and 10 mg/ml solution for
infusion**

Submission by UCB Pharma Ltd

**Recommendation of the All Wales Medicines Strategy
Group**

**Lacosamide (Vimpat®) is recommended as an option for use within
NHS Wales as adjunctive therapy in the treatment of partial-onset
seizures with or without secondary generalisation in children from
2 years of age to ≤ 15 years of age with epilepsy.**

Additional note(s):

- This advice incorporates and replaces the AWMSG recommendation for lacosamide (Vimpat®) as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from ≥ 4 years of age to ≤ 15 years of age (advice number 0318, originally published March 2018).
- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 4698), which includes the All Wales Toxicology and Therapeutics Centre (AWTTC) assessment form, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review after three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation –
1722:
Lacosamide (Vimpat®) 50 mg, 100 mg, 150 mg, 200 mg film-coated tablets,
10 mg/ml syrup, and 10 mg/ml solution for infusion September 2022

